tumor necrosis factor-related apoptosis-inducing ligand / BID Cancer Research Results

TRAIL/rTRAIL, tumor necrosis factor-related apoptosis-inducing ligand: Click to Expand ⟱
Features:

Recombinant TRAIL - Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

Recommended Abbreviation: rTRAIL

Alternative Names: Recombinant TRAIL, recombinant TNFSF10, Apo2L/TRAIL

Type: Recombinant protein / biologic anticancer agent / death-receptor agonist

Function: Recombinant TRAIL binds primarily to the death receptors DR4 (TNFRSF10A) and DR5 (TNFRSF10B), causing death-inducing signaling complex formation, caspase-8 activation, downstream caspase activation, and apoptosis. Many cancer cells are more sensitive to TRAIL-induced apoptosis than normal cells, although resistance is common.

Cancer: ↑ TRAIL-induced death-receptor signaling is generally favorable because it promotes extrinsic apoptosis in susceptible cancer cells. Recombinant TRAIL and TRAIL-receptor agonists have shown substantial preclinical anticancer activity, although clinical efficacy has been limited by short circulating half-life, receptor biology, and intrinsic or acquired TRAIL resistance.
BID, BH3 interacting-domain death agonist: Click to Expand ⟱
Source:
Type: pro-apoptotic protein
Bid is an abundant pro-apoptotic protein of the Bcl-2 family that is crucial for death receptor-mediated apoptosis in many cell systems.
The expression of BID can serve as a prognostic marker in several cancers. Higher levels of BID are often associated with increased apoptosis and better treatment responses, while lower levels may indicate resistance to therapy and poorer outcomes.

Generation of Truncated Bid (tBid):
• When apoptosis is signaled, specific proteases (such as caspase-8) cleave full-length Bid into its truncated form, tBid.
• tBid is the active form that translocates to mitochondria.

So "the truncation of Bid" means that the protein has been converted into an active form (tBid) that supports apoptosis.
Scientific Papers found: Click to Expand⟱
8152- lamb,  TRAIL/rTRAIL,    Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4
- in-vitro, NSCLC, A549 - in-vitro, Lung, H1299
TumCD↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, Bcl-2↓, cFLIP↓, XIAP↓, BID↑, DR4↑, p‑NF-kB↓, p‑IκB↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Cell Death(tgid=5) ⓘ

Bcl-2↓, 1,   BID↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   cFLIP↓, 1,   DR4↑, 1,   TumCD↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

p‑IκB↓, 1,   p‑NF-kB↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: BID, BH3 interacting-domain death agonist
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:474  Target#:466  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page